Don’t let your most promising drug be shelved in clinical trials!

Join us to discover potential toxicities in early stage discovery and plan ahead for success at Informa Life Sciences’ 2011 Protein Kinases Congress.

Novel Enzymes: Drugging undruggable targets

Attend this focused session to hear a series of presentations on novel targets and pathways including HDAC, PARP and others.

Targeting acetyl lysine epigenetic reader domains
Stefan Knapp, Principal Investigator, Phosphorylation Dependent Signaling Group, SGC – Oxford University, UK

Design & development of a novel class of HDAC inhibitors for the treatment of immune-inflammatory diseases & cancer
Stephen Shuttleworth, CSO, Karus Therapeutics, UK

Targeting class-2 HDACs: Discovery of novel and selective inhibitors by High-Throughput Screening
Daniele Carettoni, Head, Biochemistry, Axxam, Italy

Screening Methodologies for Drug Discovery Targets
9.00 Registration • 9.30 Start • 12.30 Inclusive networking dinner
Chaired by: Dr. Rochdi Bouhelal, Research Investigator, Centre for Proteomics Research, Novartis, Switzerland
This interactive workshop will focus on novel screening methodologies for drug discovery targets including case study examples for GPCR, Ion Channels and Protein Kinase targets.